Novartis AG (NVS) : Thursdays money flow indicated an uptick to downtick ratio was at 1.22. The total value of inflow transactions on upticks was $11.75 million, whereas, the total value of outflow trades on downticks was $9.64 million. The total money flow was $2.11 million, which shows a mild bullish bias. The total money flow into the stock in block trades was $1.47 million. The total value of the trades done on upticks was $1.47 million. Novartis AG (NVS) was trading with a -0.43% change over previous days close. It fell $0.35 during the day and reached $81.67. The stock was -1.26% compared to the previous weeks close.
Novartis AG (NVS) : The highest short term price target forecast on Novartis AG (NVS) is $115 and the lowest target price is $81. A total of 4 equity analysts are currently covering the company. The average price of all the analysts is $92.75 with a standard deviation of $15.2. The stock has recorded a 20-day Moving Average of 2.98% and the 50-Day Moving Average is 4.81%.
Novartis AG (NYSE:NVS): The stock opened at $81.71 on Thursday but the bulls could not build on the opening and the stock topped out at $82.16 for the day. The stock traded down to $81.42 during the day, due to lack of any buying support eventually closed down at $81.80 with a loss of -0.27% for the day. The stock had closed at $82.02 on the previous day. The total traded volume was 1,299,749 shares.
Novartis AG is a holding company that, through its subsidiaries, is engaged in development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals around the world. Its portfolio includes medicines, eye care, generic pharmaceuticals, preventive vaccines and over-the-counter (OTC) products. The Companys segments include Pharmaceuticals, which include patent-protected prescription medicines; Alcon, which include surgical, ophthalmic pharmaceutical and vision care products; Sandoz, which include generic pharmaceuticals, and Consumer Health, which includes the OTC Division. Pharmaceuticals products include Afinitor/Votubia, Exjade, Galvus, Exforge and Voltaren, among others. Its Sandoz products include Valsartan (Diovan), Cyclophosphamide injection and AirFluSal Forspiro, among others. Its OTC offers readily available consumer medicine. The Company operates Admune Therapeutics as a wholly owned subsidiary.